MannKind/$MNKD
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About MannKind
MannKind Corp is a biopharmaceutical company dedicated to transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
- Ticker
- $MNKD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 592
- Headquarters
- Danbury, United States
- Website
- mannkindcorp.com
MannKind Metrics
BasicAdvanced
$1.3B
-
-$0.16
1.10
-
Price and volume
Market cap
$1.3B
Beta
1.1
52-week high
$6.51
52-week low
$2.23
Average daily volume
4.2M
Financial strength
Current ratio
1.719
Quick ratio
1.287
Long term debt to equity
-6.269
Total debt to equity
-6.456
Interest coverage (TTM)
0.15%
Profitability
EBITDA (TTM)
19.535
Gross margin (TTM)
75.39%
Net profit margin (TTM)
-11.08%
Operating margin (TTM)
1.85%
Effective tax rate (TTM)
10.36%
Revenue per employee (TTM)
$660,000
Management effectiveness
Return on assets (TTM)
0.79%
Return on equity (TTM)
71.36%
Valuation
Price to revenue (TTM)
2.762
Price to book
-18.13
Price to tangible book (TTM)
-2.7
Price to free cash flow (TTM)
-59.957
Free cash flow yield (TTM)
-1.67%
Free cash flow per share (TTM)
-0.066
Growth
Revenue change (TTM)
30.45%
Earnings per share change (TTM)
-245.69%
3-year revenue growth (CAGR)
35.53%
3-year earnings per share growth (CAGR)
-4.94%
10-year earnings per share growth (CAGR)
-28.09%
What the Analysts think about MannKind
Analyst ratings (Buy, Hold, Sell) for MannKind stock.
Analyst projections of the future price of MannKind stock.
Bulls say / Bears say
Furoscix sales reached $22.2 million in Q2, up 43% from Q1, while doses bought by health-system networks also rose. FDA approval of the ReadyFlow autoinjector adds a quicker-to-use format that could support further uptake. (MannKind Corporation)
Afrezza’s new approval for children aged six and older opens a new patient group. Early launch signs include prescriptions from one-third of the top 100 paediatric insulin writers and all 20 priority accounts. (MannKind Corporation)
MannKind’s inhaled nintedanib candidate for idiopathic pulmonary fibrosis cleared an early hurdle: its Phase 1b study showed safety and tolerability in patients, and the global Phase 2 study is under way. Further trials could create a new growth stream, though efficacy remains to be established. (MannKind Corporation)
Afrezza sales remain weak despite the paediatric launch opportunity: Q2 sales fell 7% year on year to $17.0 million, and first-half sales were down 3%. (MannKind Corporation)
Revenue growth has not yet translated into earnings: MannKind reported a $19.0 million Q2 net loss and a $35.7 million loss for the first half. It also had $319.1 million of term-loan debt and raised $50 million in July, with much of that financing needed for a milestone payment. (StockTitan, SEC)
MannKind remains heavily reliant on United Therapeutics: the partner accounted for about 61% of revenue in the first half of 2026. A slowdown in its business or a change in the relationship could therefore materially affect MannKind’s results. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 27 Oct 2026.
MannKind Financial Performance
Revenues and expenses
MannKind Earnings Performance
Company profitability
Upcoming events
No upcoming events
MannKind News
AllArticlesVideos
MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth
MarketBeat2 weeks ago
This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Benzinga2 weeks ago
MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum
MarketBeat2 months ago
Funds containing MannKind
Fund name | Fund size | $MNKD weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.08% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.08% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.04% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.04% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.